460 related articles for article (PubMed ID: 26193961)
1. Personalized medicine approach for optimizing the dose of tafamidis to potentially ameliorate wild-type transthyretin amyloidosis (cardiomyopathy).
Cho Y; Baranczak A; Helmke S; Teruya S; Horn EM; Maurer MS; Kelly JW
Amyloid; 2015; 22(3):175-80. PubMed ID: 26193961
[TBL] [Abstract][Full Text] [Related]
2. Blinded potency comparison of transthyretin kinetic stabilisers by subunit exchange in human plasma.
Nelson LT; Paxman RJ; Xu J; Webb B; Powers ET; Kelly JW
Amyloid; 2021 Mar; 28(1):24-29. PubMed ID: 32811187
[TBL] [Abstract][Full Text] [Related]
3. Tafamidis for transthyretin amyloidosis.
de Lartigue J
Drugs Today (Barc); 2012 May; 48(5):331-7. PubMed ID: 22645721
[TBL] [Abstract][Full Text] [Related]
4. Tafamidis in transthyretin amyloid cardiomyopathy: effects on transthyretin stabilization and clinical outcomes.
Maurer MS; Grogan DR; Judge DP; Mundayat R; Packman J; Lombardo I; Quyyumi AA; Aarts J; Falk RH
Circ Heart Fail; 2015 May; 8(3):519-26. PubMed ID: 25872787
[TBL] [Abstract][Full Text] [Related]
5. Tafamidis: a selective transthyretin stabilizer to treat wild-type ATTR amyloidosis and hereditary ATTR amyloidosis with cardiomyopathy.
Paton DM
Drugs Today (Barc); 2019 Dec; 55(12):727-734. PubMed ID: 31942875
[TBL] [Abstract][Full Text] [Related]
6. Semi-quantitative models for identifying potent and selective transthyretin amyloidogenesis inhibitors.
Connelly S; Mortenson DE; Choi S; Wilson IA; Powers ET; Kelly JW; Johnson SM
Bioorg Med Chem Lett; 2017 Aug; 27(15):3441-3449. PubMed ID: 28625364
[TBL] [Abstract][Full Text] [Related]
7. Tafamidis in the Treatment of ATTR-related Cardiomyopathy: Indications and Grey Zones.
Capovilla TM; Lalario A; Rossi M; Porcari A; Aimo A; Limongelli G; Emdin M; Merlo M; Sinagra G
Heart Fail Clin; 2024 Jul; 20(3):333-341. PubMed ID: 38844304
[TBL] [Abstract][Full Text] [Related]
8. Tafamidis concentration required for transthyretin stabilisation in cerebrospinal fluid.
Tsai FJ; Jaeger M; Coelho T; Powers ET; Kelly JW
Amyloid; 2023 Sep; 30(3):279-289. PubMed ID: 36691999
[TBL] [Abstract][Full Text] [Related]
9. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.
Bulawa CE; Connelly S; Devit M; Wang L; Weigel C; Fleming JA; Packman J; Powers ET; Wiseman RL; Foss TR; Wilson IA; Kelly JW; Labaudinière R
Proc Natl Acad Sci U S A; 2012 Jun; 109(24):9629-34. PubMed ID: 22645360
[TBL] [Abstract][Full Text] [Related]
10. Tafamidis: A First-in-Class Transthyretin Stabilizer for Transthyretin Amyloid Cardiomyopathy.
Park J; Egolum U; Parker S; Andrews E; Ombengi D; Ling H
Ann Pharmacother; 2020 May; 54(5):470-477. PubMed ID: 31735059
[No Abstract] [Full Text] [Related]
11. Relationship of binding-site occupancy, transthyretin stabilisation and disease modification in patients with tafamidis-treated transthyretin amyloid cardiomyopathy.
Tess DA; Maurer TS; Li Z; Bulawa C; Fleming J; Moody AT
Amyloid; 2023 Jun; 30(2):208-219. PubMed ID: 36399070
[TBL] [Abstract][Full Text] [Related]
12. AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin.
Penchala SC; Connelly S; Wang Y; Park MS; Zhao L; Baranczak A; Rappley I; Vogel H; Liedtke M; Witteles RM; Powers ET; Reixach N; Chan WK; Wilson IA; Kelly JW; Graef IA; Alhamadsheh MM
Proc Natl Acad Sci U S A; 2013 Jun; 110(24):9992-7. PubMed ID: 23716704
[TBL] [Abstract][Full Text] [Related]
13. A Comprehensive Review on Chemistry and Biology of Tafamidis in Transthyretin Amyloidosis.
Patil MB; Ghode P; Joshi P
Mini Rev Med Chem; 2024; 24(6):571-587. PubMed ID: 37828667
[TBL] [Abstract][Full Text] [Related]
14. Tafamidis (Vyndaqel): a light for FAP patients.
Nencetti S; Rossello A; Orlandini E
ChemMedChem; 2013 Oct; 8(10):1617-9. PubMed ID: 24000164
[TBL] [Abstract][Full Text] [Related]
15. Recent progress in the understanding and treatment of transthyretin amyloidosis.
Sekijima Y
J Clin Pharm Ther; 2014 Jun; 39(3):225-33. PubMed ID: 24749898
[TBL] [Abstract][Full Text] [Related]
16. Quantification of transthyretin kinetic stability in human plasma using subunit exchange.
Rappley I; Monteiro C; Novais M; Baranczak A; Solis G; Wiseman RL; Helmke S; Maurer MS; Coelho T; Powers ET; Kelly JW
Biochemistry; 2014 Apr; 53(12):1993-2006. PubMed ID: 24661308
[TBL] [Abstract][Full Text] [Related]
17. Failure of Tafamidis to Halt Progression of Ala36Pro TTR Oculomeningovascular Amyloidosis.
Salvi F; Volpe R; Pastorelli F; Bianchi A; Vella A; Rapezzi C; Mascalchi M
J Stroke Cerebrovasc Dis; 2018 Sep; 27(9):e212-e214. PubMed ID: 29779881
[TBL] [Abstract][Full Text] [Related]
18. Tafamidis: A Novel Treatment for Transthyretin Amyloid Cardiomyopathy.
Nawarskas JJ; Shephard EA
Cardiol Rev; 2020; 28(3):156-160. PubMed ID: 32101907
[TBL] [Abstract][Full Text] [Related]
19. Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy.
Maurer MS; Schwartz JH; Gundapaneni B; Elliott PM; Merlini G; Waddington-Cruz M; Kristen AV; Grogan M; Witteles R; Damy T; Drachman BM; Shah SJ; Hanna M; Judge DP; Barsdorf AI; Huber P; Patterson TA; Riley S; Schumacher J; Stewart M; Sultan MB; Rapezzi C;
N Engl J Med; 2018 Sep; 379(11):1007-1016. PubMed ID: 30145929
[TBL] [Abstract][Full Text] [Related]
20. Monitoring treatment response to tafamidis by serial native T1 and extracellular volume in transthyretin amyloid cardiomyopathy.
Shintani Y; Okada A; Morita Y; Hamatani Y; Amano M; Takahama H; Amaki M; Hasegawa T; Ohta-Ogo K; Kanzaki H; Ishibashi-Ueda H; Yasuda S; Shimazaki C; Yoshinaga T; Yazaki M; Sekijima Y; Izumi C
ESC Heart Fail; 2019 Feb; 6(1):232-236. PubMed ID: 30478886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
